Hospital Universitario Dr. Jose E. Gonzalez
Clinical trials sponsored by Hospital Universitario Dr. Jose E. Gonzalez, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a diabetes pill also calm psoriasis? new study aims to find out Results expected Feb 2027 (estimated)
- Gut health supplement may calm inflammation in kidney dialysis patients Results expected Jun 2027 (estimated)
- New combo aims to boost transplant success in tough lymphoma Results expected Sep 2027 (estimated)
-
Gut health supplement may calm inflammation in kidney dialysis patients
Disease control Recruiting nowThis trial tests whether a daily capsule containing probiotics and prebiotics can lower inflammation and improve nutrition in adults with chronic kidney disease who are on peritoneal dialysis. Participants take either the synbiotic or a placebo for six months, with blood tests an…
Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo aims to boost transplant success in tough lymphoma
Disease control Recruiting nowThis study tests a combination of two chemotherapy drugs (gemcitabine and oxaliplatin) plus a low dose of the immunotherapy epcoritamab in 10 people whose diffuse large B-cell lymphoma has come back or not responded to prior treatment. Participants must be eligible for a stem cel…
Phase 2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a diabetes pill also calm psoriasis? new study aims to find out
Disease control Recruiting nowThis study tests whether adding semaglutide (a drug used for diabetes and weight loss) to a standard topical cream can improve psoriasis symptoms and reduce body-wide inflammation. About 62 adults with plaque psoriasis who are overweight or have type 2 diabetes will receive eithe…
Phase 4 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising combo aims to beat relapsed leukemia
Disease control Recruiting nowThis phase 2 trial tests whether adding a low dose of venetoclax (a targeted drug) with itraconazole to standard chemotherapy can improve remission rates in people with relapsed or refractory acute lymphoblastic leukemia. The study enrolls 12 adults whose leukemia has returned or…
Phase 2 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC